News

Zelenectide pevedotin shows promising antitumor activity and manageable safety in advanced solid tumors, particularly urothelial carcinoma, in recent clinical trials.

Recent trials at ESMO Congress 2025 clarify treatment options for metastatic renal cell carcinoma, highlighting promising combinations and emerging therapies.

During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.

Join the 43rd Annual Chemotherapy Foundation Symposium in New York City for cutting-edge cancer care education and networking opportunities.

Study data reveal key risk factors for pneumonitis in patients with metastatic breast cancer treated with T-DXd, highlighting the need for proactive management strategies.

New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach.

A phase 1b trial reveals the safety and potential efficacy of combining PolyPEPI1018 vaccine with TAS-102 in treating advanced colorectal cancer.

Glofitamab and polatuzumab vedotin show promising efficacy and safety in treating relapsed/refractory large B-cell lymphoma, with durable responses reported.

Belzutifan shows promising disease control and manageable safety in advanced VHL disease, with notable tumor responses and anemia as a common adverse effect.

Discover the latest breakthroughs in oncology, including FDA approvals, practice-changing trials, and insights on global cancer research disparities.

Innovations in cancer immunotherapy highlight the urgent need for effective management of immune-related toxicities, emphasizing precision medicine and interdisciplinary collaboration.

A recent study reveals that medication burden significantly increases acute care use in older metastatic prostate cancer patients on androgen receptor inhibitors.

Izalontamab shows promise as a safe treatment for advanced epithelial tumors, demonstrating early antitumor activity in a recent clinical trial.

A study reveals that lower KIM-1 levels predict better outcomes in advanced renal cell carcinoma patients treated with nivolumab and ipilimumab.

New trial results reveal sacituzumab govitecan shows promise for HR+/HER2– metastatic breast cancer, despite missing primary survival goals.

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced urothelial cancer patients, challenging traditional treatment durations.

UGN-103 shows promising 77.8% efficacy in treating recurrent low-grade bladder cancer, paving the way for a potential FDA approval.

The FDA has approved daratumumab and hyaluronidase for the treatment of patients with high-risk smoldering multiple myeloma.

Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

The FDA designates M2T-CD33 as an orphan drug, highlighting its potential as a safer, innovative treatment for acute myeloid leukemia.

The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.

Talquetamab and daratumumab show high efficacy in treating relapsed/refractory multiple myeloma, with promising response rates and manageable safety profiles.

During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.